Version 7 2022-10-06, 08:58Version 7 2022-10-06, 08:58
Version 6 2022-10-06, 08:44Version 6 2022-10-06, 08:44
Version 5 2022-10-06, 08:43Version 5 2022-10-06, 08:43
Version 4 2022-10-06, 08:37Version 4 2022-10-06, 08:37
Version 3 2022-10-06, 08:28Version 3 2022-10-06, 08:28
Version 2 2022-10-06, 08:27Version 2 2022-10-06, 08:27
Version 1 2022-10-06, 08:19Version 1 2022-10-06, 08:19
journal contribution
posted on 2022-10-06, 08:58authored byPetros Grivas, John A. Blake-Haskins, Nuno Costa, Bo Huang, Robert J. Laliberte, Daniel P. Petrylak, Jeanny B. Aragon-Ching, Joaquim Bellmunt, Cora N. Sternberg, Evgeny Kopyltsov, Norihiko Tsuchiya, Srikala S. Sridhar, Yohann Loriot, Anders Ullén, Wim Demey, Sinisa Radulović, Haralabos Kalofonos, Howard Gurney, Begoña P. Valderrama, Claudia Caserta, Eric Voog, Se-Hoon Park, Thomas Powles
German translation of the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer